OBJECTIVE To determine different haemostatic tests in patients with various degrees of liver parenchymal damage and to rule out their role in assessing parenchymal hepatocyte dysfunction. METHODS Seventy-five patients with chronic liver disease were included and due to their degree of liver damage categorized into three groups: group one patients with chronic viral hepatitis and early stage o...

Portal hypertension is a direct consequence of hepatic fibrosis, and several hepatic fibrosis markers have been evaluated as a noninvasive alternative to the detection of portal hypertension and esophageal varices. In the present study, we compared the diagnostic and prognostic values of the noninvasive fibrosis markers in patients with alcoholic cirrhosis. A total of 219 consecutive alcoholic ...

In the general population, C-reactive protein (CRP) level increases in the presence of acute or chronic inflammation and infections. In patients with cirrhosis, the basal level is higher than in patients without cirrhosis, due to chronic hepatic and other inflammation, but when infection occurs the more severe the underlying liver dysfunction, the lower the increase in CRP. Therefore, the predi...

Dysregulated erythropoietin (EPO) plasma levels may play a role in the patho physiology of chronic liver disease (CLD) [1] because chronic anaemia is frequently observed in patients with liver cirrhosis. Some reports have used regular short acting Erythropoietin as well as low dose long acting Erythropoietin and regular short acting Granulocyte colony stimulating factor (Filgrastim) in liver ci...

Non-alcoholic steatohepatitis has emerged as a major public health problem, and the burden of non-alcoholic cirrhosis is projected to increase by 64%-156% 2030. The threat aggravated fact that are currently no approved drugs for treatment steatohepatitis. In this paper, we review main challenges drug development in patients with cirrhosis, describe opportunities brought advances understanding c...

Background: Acute kidney injury remains a common complication with poor prognosis, and is significant predictor of mortality in cirrhosis patients. We aimed to determine the percentage acute decompensated patients evaluate treatment results as well several factors related Methods: A prospective study was conducted on Can Tho City, Vietnam, from 2019 2020. Decompensated were found have admission...

Although only the expansion of the donor pool will have a major impact on the survival of patients with decompensated cirrhosis awaiting OLT, anticipation of complications such as SBP may improve the likelihood of a patient surviving until OLT, and may ameliorate some of the major causes of morbidity of cirrhosis, such as osteoporosis. Close communication between the treating physicians and the...

The prevalence of cirrhosis has risen significantly over recent decades and is predicted to rise further. Widespread use non-invasive testing means increasingly diagnosed at an earlier stage. Despite this, there are significant variations in outcomes patients with across the UK, areas higher levels deprivation more likely die from their liver disease. This three-part best practice guidance aims...

Infections in patients with cirrhosis are common among those who develop variceal hemorrhage. Prophylactic antimicrobial treatment with third generation cephalosporins is recommended in patients with advanced cirrhosis and gastrointestinal hemorrhage. However no infectious source is identified in up to 50% of patients with cirrhosis and clinical sepsis. We report the first case of Paracoccus ye...

PURPOSE OF REVIEW This article reviews treatment options of the approved and soon-to-be approved direct-acting antivirals (DAA)-based therapies in individuals with hepatitis C virus (HCV) cirrhosis. RECENT FINDINGS DAA-based therapies have been shown to be well tolerated and effective in achieving viral cure in individuals with compensated and decompensated cirrhosis. Preliminary studies sugg...